Physician profile
Nicholas Taylor
NPI 1184172207
$1,790.64
in general payments reported to CMS, 2019-2025
14 companies · $321 in 2025
The $321 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.36 · 2020: $114 · 2021: $539 · 2022: $241 · 2023: $409 · 2024: $94.05 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $823.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $362.24 | 2022-2025 | Infuse |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $261.05 | 2019-2021 | |
| Alcon Vision LLC | $209.66 | 2019-2025 | Total30, Dailies Total1, Precision7 |
| Glaukos Corporation | $188.24 | 2025 | Photrexa Viscous and Photrexa |
| Coopervision INC. | $142.26 | 2021-2025 | Myday Contact Lens, Clariti Contact Lens |
| Johnson & Johnson Vision Care, INC. | $125.98 | 2019-2022 | |
| Optos, INC. | $121.48 | 2021 | |
| Maculogix, INC. | $102.44 | 2021 | |
| Ivantis, INC | $77.59 | 2020 | |
| Regeneron Pharmaceuticals, INC. | $71.24 | 2023 | Eylea Hd |
| Carl Zeiss Meditec USA, INC. | $67.05 | 2023 | Clarus |
| Allergan, INC. | $33.69 | 2022 | |
| Oyster Point Pharma, INC. | $22.13 | 2024 | Ryzumvi, Tyrvaya |
| Abb Con-Cise Optical Group LLC | $5.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.